Q4 Earnings Forecast for BCRX Issued By HC Wainwright

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on Monday, December 15th. HC Wainwright analyst A. Fein expects that the biotechnology company will earn $0.02 per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at $0.05 EPS, FY2028 earnings at $0.88 EPS and FY2029 earnings at $1.31 EPS.

Other equities research analysts also recently issued research reports about the company. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday. Citizens Jmp lowered their price target on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Barclays dropped their price target on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. Finally, Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $7.29 on Wednesday. The firm has a fifty day moving average price of $7.17 and a two-hundred day moving average price of $8.16. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -145.80, a PEG ratio of 0.69 and a beta of 0.91. BioCryst Pharmaceuticals has a one year low of $6.00 and a one year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. During the same period last year, the company posted ($0.07) EPS. The business’s revenue was up 36.1% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. Nuveen LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $10,677,000. Russell Investments Group Ltd. raised its position in BioCryst Pharmaceuticals by 269.5% in the 1st quarter. Russell Investments Group Ltd. now owns 103,329 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 75,363 shares during the period. Wellington Management Group LLP lifted its stake in BioCryst Pharmaceuticals by 2.6% in the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after purchasing an additional 2,291 shares during the last quarter. EntryPoint Capital LLC bought a new stake in BioCryst Pharmaceuticals in the first quarter worth $304,000. Finally, AlphaQuest LLC boosted its position in BioCryst Pharmaceuticals by 120.3% during the first quarter. AlphaQuest LLC now owns 62,646 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 34,204 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.10, for a total transaction of $646,128.40. Following the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at approximately $2,954,679.20. This trade represents a 17.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 161,680 shares of company stock worth $1,164,401. 5.10% of the stock is currently owned by corporate insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.